Group One Trading
CYCN icon

Group One Trading’s Cyclerion Therapeutics CYCN Stock Holding History

Group One Trading’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-17,900
Closed -$60K – 7194
2023
Q4 		$60K Hold
17,900
– – ﹤0.01% 4915
2023
Q3 		$60.9K Hold
17,900
– – ﹤0.01% 4900
2023
Q2 		$73.6K Buy
17,900
+16,960
+1,804% +$87.8K ﹤0.01% 4934
2023
Q1 		$8.15K Sell
940
-325
-26% -$4.1K ﹤0.01% 6050
2022
Q4 		$16.6K Sell
1,265
-185
-13% -$2.19K ﹤0.01% 5718
2022
Q3 		$25K Sell
1,450
-145
-9% -$2.49K ﹤0.01% 5917
2022
Q2 		$18K Sell
1,595
-230
-13% -$3.29K ﹤0.01% 6355
2022
Q1 		$41K Sell
1,825
-110
-6% -$2.65K ﹤0.01% 6246
2021
Q4 		$67K Sell
1,935
-4,210
-69% -$199K ﹤0.01% 6089
2021
Q3 		$377K Buy
6,145
+3,835
+166% +$251K ﹤0.01% 4506
2021
Q2 		$180K Buy
2,310
+2,290
+11,450% +$143K ﹤0.01% 5345
2021
Q1 		$1K Sell
20
-320
-94% -$24K ﹤0.01% 7448
2020
Q4 		$21K Buy
+340
New +$23.2K ﹤0.01% 5491

Other funds holding CYCN

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KA
Kovack Advisors Ft. Lauderdale, Florida $2.08B AUM 38.95% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
AWM
Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return

Group One Trading's CYCN Position: Q1 2026 in Review

Group One Trading held its Cyclerion Therapeutics (CYCN) position steady in Q1 2026 at 192 shares worth $295. The position accounts for ﹤0.01% of the portfolio, ranked #7370.

Group One Trading first reported a position in CYCN in Q1 2020 and has held it in 25 quarters since. The position peaked at $104K in Q3 2021. 17 funds tracked by Wall St. Rank hold CYCN as of Q1 2026.

  • Group One Trading held 192 shares of Cyclerion Therapeutics worth $295 as of Q1 2026.
  • Group One Trading left its Cyclerion Therapeutics share count unchanged in Q1 2026.
  • Cyclerion Therapeutics made up ﹤0.01% of Group One Trading's portfolio in Q1 2026, its #7370 holding.
  • Group One Trading first reported a position in Cyclerion Therapeutics in Q1 2020 and has held it in 25 quarters since.
  • Group One Trading's Cyclerion Therapeutics position peaked at $104K in Q3 2021.
  • 17 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.